Pharma Lifesciences & Medtech

From innovation to regulation and digitisation

Important challenges in pharma lifesciences & medtech

Pharmaceutical and medical technology companies face major challenges in an increasingly integrated and patient-oriented environment. The global demand for innovative and affordable medicines and treatments continues to grow, but at the same time legislators, health insurers, healthcare providers and patients strive for the most favorable price/quality ratio, proven effectiveness of products and more transparency.

What can you expect from us?

Together with our clients, ranging from small life sciences entrepreneurs, start-ups to large multinationals, we can help you make future-proof strategic choices around R&D or supply chain, for example. In doing so, we can help you with the transformation processes necessary to actually implement these choices within the boundaries of strict regulations.

Our team

We offer a multidisciplinary Pharma Lifesciences & Medtech team. In close collaboration with international teams, we advise companies in the sector and connect them in the industry and related sectors such as the healthcare sector and insurance sector.

Insights and publications

41 results

25/03/25

Dutch M&A Trends in Pharma & Life Sciences and Healthcare

Insights into the anticipated trends in the Dutch Pharma & Life Sciences (PLS) and Healthcare sectors for 2025

05/03/25

Navigating the new EU Omnibus Simplification Package

Discover how the new EU Omnibus package reshapes sustainability reporting. PwC expert Ellen McCready shares key insights on navigating these changes.

23/01/25

Double materiality and biodiversity: three recommendations for success

Experience shows that the materiality of biodiversity is often greater than expected. By following our recommendations, companies can effectively include biodiversity in their DMA process and ensure a good score in their reporting and strategy.